Literature DB >> 6615691

Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.

M J Dew, R E Ryder, N Evans, B K Evans, J Rhodes.   

Abstract

5-amino salicylic acid coated with acrylic based resin was given orally to eight patients with active ulcerative colitis. Abdominal X-rays confirmed that the preparation released its contents in the terminal ileum and proximal colon. Differences between individuals were marked; the plasma 'concentration-time profile' reflected variations in the time taken for tablets to reach the terminal ileum.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6615691      PMCID： PMC1427967          DOI： 10.1111/j.1365-2125.1983.tb04983.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  4 in total

1.  Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.

Authors:  M J Dew; P Hughes; A D Harries; G Williams; B K Evans; J Rhodes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

2.  HA-966 effects on striatal dopamine metabolism: implications for dopamine compartmentalization.

Authors:  H J Broxterman; C F van Valkenburg; E L Noach
Journal:  J Pharm Pharmacol       Date:  1980-01       Impact factor: 3.765

3.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

4.  An oral preparation to release drugs in the human colon.

Authors:  M J Dew; P J Hughes; M G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335
  4 in total
  25 in total

Review 1.  ["Targeted delivery" in the gastrointestinal tract].

Authors:  C S Leopold
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 2.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease.

Authors:  J Fallingborg; P Pedersen; B A Jacobsen
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 5.  Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.

Authors:  S G Nugent; D Kumar; D S Rampton; D F Evans
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

6.  Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.

Authors:  N Mahmud; D G Weir; D Kelleher
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

7.  Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss.

Authors:  E A Masson; J M Rhodes
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

Review 8.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

9.  Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children.

Authors:  L A Christensen; J Fallingborg; B A Jacobsen; K Abildgaard; H H Rasmussen; S N Rasmussen; S H Hansen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

10.  Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.

Authors:  B Myers; D N Evans; J Rhodes; B K Evans; B R Hughes; M G Lee; A Richens; D Richards
Journal:  Gut       Date:  1987-02       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.